{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:48:48Z","timestamp":1782460128284,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01515-w","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:16:25Z","timestamp":1782458185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Second-Line FOLFIRI Plus Ramucirumab According to Prior Biologic Exposure in Metastatic Colorectal Cancer: A Retrospective Comparison of Prior Bevacizumab and Prior Anti-EGFR Cohorts"],"prefix":"10.1007","volume":"57","author":[{"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4.","journal-title":"Lancet Oncol"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab versus bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: the PARADIGM randomized clinical trial. JAMA. 2023;329:1271\u201382. https:\/\/doi.org\/10.1001\/jama.2023.4428.","journal-title":"JAMA"},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.007.","journal-title":"Eur J Cancer"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomized, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0.","journal-title":"Lancet Oncol"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1093\/annonc\/mdw402","volume":"27","author":"R Obermannova","year":"2016","unstructured":"Obermannova R, Van Cutsem E, Yoshino T, Bodoky G, Prausova J, Garcia-Carbonero R, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and fluorouracil plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016;27:2082\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdw402.","journal-title":"Ann Oncol"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2017.03.005","volume":"78","author":"T Yoshino","year":"2017","unstructured":"Yoshino T, Tabernero J, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, et al. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Eur J Cancer. 2017;78:61\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.005.","journal-title":"Eur J Cancer"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506. https:\/\/doi.org\/10.1200\/JCO.2012.42.8201.","journal-title":"J Clin Oncol"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol. 2013;14:29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(12)70477-1.","journal-title":"Lancet Oncol"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.esmoop.2023.101636","volume":"8","author":"H Yasui","year":"2023","unstructured":"Yasui H, Okita Y, Nakamura M, Sagawa T, Watanabe T, Kataoka K, et al. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. ESMO Open. 2023;8:101636. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101636.","journal-title":"ESMO Open"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-019-03855-w","volume":"84","author":"T Suzuki","year":"2019","unstructured":"Suzuki T, Shinozaki E, Osumi H, Nakayama I, Ota Y, Ichimura T, et al. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2019;84:307\u201313. https:\/\/doi.org\/10.1007\/s00280-019-03855-w.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cancers12051259","volume":"12","author":"A Parisi","year":"2020","unstructured":"Parisi A, Cortellini A, Cannita K, Venditti O, Gelibter A, Biondani P, et al. Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: the multicenter SLAVE study. Cancers (Basel). 2020;12:1259. https:\/\/doi.org\/10.3390\/cancers12051259.","journal-title":"Cancers (Basel)"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000453336","volume":"92","author":"H Hasegawa","year":"2017","unstructured":"Hasegawa H, Taniguchi H, Mitani S, Kadowaki S, Komori A, Narita Y, et al. Efficacy of second-line bevacizumab-containing chemotherapy for patients with metastatic colorectal cancer following first-line treatment with an anti-epidermal growth factor receptor antibody. Oncology. 2017;92:205\u201312. https:\/\/doi.org\/10.1159\/000453336.","journal-title":"Oncology"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1515_CR15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published November 27, 2017. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9.","journal-title":"Lancet Oncol"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in metastatic colorectal cancer (TRIBE2). Lancet Oncol. 2020;21:497\u2013507. https:\/\/doi.org\/10.1016\/S1470-2045(19)30862-9.","journal-title":"Lancet Oncol"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40801-023-00366-2","volume":"10","author":"T Masuishi","year":"2023","unstructured":"Masuishi T, Nagaoka S, Jin L, Yoshizawa K. Post-marketing safety study of ramucirumab plus FOLFIRI: analysis of age and initial dose of irinotecan in patients with metastatic colorectal cancer. Drugs Real World Outcomes. 2023;10:405\u201313. https:\/\/doi.org\/10.1007\/s40801-023-00366-2.","journal-title":"Drugs Real World Outcomes"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s10147-023-02357-3","volume":"28","author":"S Dote","year":"2023","unstructured":"Dote S, Shiwaku E, Kohno E, et al. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study. Int J Clin Oncol. 2023;28:1054\u201362. https:\/\/doi.org\/10.1007\/s10147-023-02357-3.","journal-title":"Int J Clin Oncol"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X.","journal-title":"Lancet"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1414325.","journal-title":"N Engl J Med"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","journal-title":"N Engl J Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01515-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01515-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:16:31Z","timestamp":1782458191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01515-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01515-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the institutional ethics committee of the National Hospital Organization Hokkaido Cancer Center (approval No. 05\u201358).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}